Supriya Lifescience Ltd (NSE:SUPRIYA)

Q2 2026 Supriya Lifescience Ltd Earnings Call Transcript

Nov 12, 2025 / 05:30 AM GMT

Release Date Price: ₹786.7 (+3.19%)

Transcript

Key Points

Positve

Supriya Lifescience Ltd (BOM:543434) achieved a 20% year-on-year sales growth in Q2 FY26, reflecting strong recovery and operational resilience.
The company reported a significant improvement in EBITDA, which stood at INR 73 crores, up 12% year-on-year, with a robust EBITDA margin of 36%.
Exports accounted for 81% of the company's Q2 FY26 revenues, highlighting its strong international market presence.
The company is making substantial progress in backward integration, with 79% of FY26 revenues now fully integrated, enhancing operational efficiency.
Supriya Lifescience Ltd (BOM:543434) is on track to achieve its long-term revenue target of INR 1,000 crore by FY27, supported by a healthy product pipeline and strategic market expansion.

Negative

The company's H1 FY26 revenue growth was only 6% year-on-year, indicating a slow start to the fiscal year due to earlier operational challenges.
There were delays in the DSM project, with full revenue potential expected only in FY27, impacting short-term financial performance.
The North American market remains a small contributor to overall revenues, with challenges in scaling up product approvals and market penetration.
The company faces ongoing regulatory hurdles, which could delay the commercialization of new products and impact revenue growth.
Despite achieving strong margins, the company maintains a conservative margin guidance of 33-35%, indicating limited room for margin expansion in the near term.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SPRL.NS - Supriya Lifescience Ltd
Q2 2026 Supriya Lifescience Ltd Earnings Call
Nov 13, 2025 / 05:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, good day and welcome to the Supria Life Science Limited Q2 FY26 earnings conference call. As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing, then 0 on your touchstone phone.

I now hand the conference over to Miss Nehassanian from EYIR.

Thank you and over to you, ma'am.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, Huda.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.